Scientists have developed a novel treatment approach for persistent viral infections such as herpes. Using animal models of herpes simplex virus (HSV) infection, researchers show that blocking the activity of a host cell protein called LSD1 reduces HSV infection, shedding (release of viral particles) and recurrence. LSD1, which is essential for HSV's infectious cycle, modifies certain host proteins that control access to DNA. These modifications, known as "epigenetic" changes, help determine how and when genes are used. The collaborative effort, led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, demonstrates the potential of epigenetic therapy as an antiviral strategy.
After initial infection, HSV enters a latent state in sensory nerve cells, periodically reactivating to produce disease. HSV typically causes recurrent oral or genital lesions and can contribute to the eye disease herpetic keratitis, a leading cause of blindness. Even without symptoms, HSV-infected people can shed and transmit the virus. Current HSV treatments, which target viral proteins, do not effectively control shedding or reactivation of latent virus.
The investigators used an existing drug, tranylcypromine, to block LSD1 activity in three different animal models of HSV infection and disease. The treatment targets a very early stage of the HSV infectious cycle and greatly reduced symptoms of HSV disease, shedding and lesion recurrence. By blocking a cellular rather than viral component, the treatment may minimize the evolution of drug-resistant viruses. The results also indicate that even during latency, HSV's genetic material is subject to epigenetic changes that can be regulated with drugs. Epigenetic therapies are rapidly being developed as cancer treatments, opening the possibility to also test these drugs for antiviral activity.
###JM Hill et al. Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes. Science Translational Medicine DOI: 10.1126/scitranslmed.3010643 (2014).
Thomas M. Kristie, Ph.D., chief of the Molecular Genetics Section in NIAID's Laboratory of Viral Diseases and the senior author of the paper, is available for comment.
To schedule interviews, please contact Hillary Hoffman, (301) 402-1663, firstname.lastname@example.org.
This collaborative research effort included scientists from NIAID's Laboratory of Viral Diseases, Louisiana State University Health Sciences Center, University of Alabama at Birmingham, Cincinnati Children's Hospital Medical Center, the Food and Drug Administration and Harvard Medical School. Funding was provided by NIAID and the National Eye Institute, both NIH components, as well as other sources.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.
About the National Institutes of Health (NIH)
NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
NIH...Turning Discovery Into Health®